Why the study?
Does early administration of colchicine reduce major adverse cardiovascular events in patients with acute myocardial infarction after percutaneous coronary intervention?
Does early administration of colchicine reduce major adverse cardiovascular events in patients with acute myocardial infarction after percutaneous coronary intervention?
No takes yet. Share an insight, caveat, or question.
In contrast to previous trials in stable coronary artery disease, early administration of colchicine in patients with STEMI did not reduce major adverse cardiovascular events, highlighting the need to understand its interaction with potent antiplatelet therapies.
Laudani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: